Dr Mckenna looks at how patient-reported outcome measures have been used in oncology and how they can be better utilized to improve patient outcomes.
An enlarged historical perspective makes apparent the fundamental and positive transformation of health care initiated by the Meaningful Use program. 
In this article, the author discusses the most prominent value frameworks that have been recently developed and compare each of their methods for defining value.
Brett Wilson, CEO and founder of Walking Miracles, reponds to viewpoints published in the May issue of JCP highlighting the problem of cancer drug shortages in pediatrics.
The authors used an indirect approach to deriving health state utilities for patients with MBC by mapping HRQOL data using a published regression algorithm
A mock clinical pathway development simulation was conducted to make transparent the process of developing consensus-driven, evidence-based clinical pathways in oncology. 
George Dahlman responds to a viewpoint on chemotherapy drug shortages by detailing policy measures that have been put in place to help address this issue. 
Yoram Unguru, MD, MS, MA addresses the pervasive problem of drug shortages in cancer care and what is being done to resolve the issue.